Page values for "Azelastine"

Nav

"Medicines" values

1 row is stored for this page

Field	Field type	Value
generic	`String`	Azelastine
brand	`String`	Astelin, Astepro (intranasal); Optivar (ophthalmic); with fluticasone as Dymista
structure	`File`
classes	List of `String`, delimiter: `,`	[[:Category:H1_receptor_antagonists\|Histamine H1 receptor antagonist]] • [[:Category:Mast_cell_stabilizers\|Mast cell stabilizer]] • [[:Category:Intranasal_antihistamines\|Intranasal antihistamine]]
mechanism	`String`	'"`UNIQ--vote-000013B1-QINU`"' Topical application minimizes systemic antihistaminic burden; the characteristic bitter taste with nasal use (drainage to oropharynx) is the main tolerability issue'"`UNIQ--ref-000013B2-QINU`"'.
uses	`String`	'"`UNIQ--vote-000013B3-QINU`"', '"`UNIQ--vote-000013B4-QINU`"', '"`UNIQ--vote-000013B5-QINU`"'
starting_dose	`String`	Intranasal 0.1% or 0.15%: 1-2 sprays/nostril BID; ophthalmic 0.05%: 1 drop in each eye BID
preparations	`String`	0.1%, 0.15% intranasal spray; 0.05% ophthalmic solution; combination Dymista (azelastine 0.137 mg + fluticasone 50 mcg/spray)
fda_max	`String`	2 sprays/nostril BID
pill_id	`Text`
routes	List of `String`, delimiter: `,`	Intranasal • topical ophthalmic
onset	`String`	15 minutes
duration	`String`	12 hours
halflife	`String`	~22 hours; longer 54 hours (desmethylazelastine, active metabolite)'"`UNIQ--ref-000013B6-QINU`"'
bioavailability	`String`	Intranasal ~40% systemic; ophthalmic minimal'"`UNIQ--ref-000013B7-QINU`"'
pregnancy	`String`	Limited data; second-line to intranasal corticosteroids or PO loratadine/cetirizine.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed\|citation needed]]]</sup>
legal	`String`	OTC (Astepro 0.15%) and [[USLegal:Prescription only\|Rx-only]] (other intranasal, ophthalmic, Dymista) in US